FluxMPS™ RPMI 1640 Medium, High Glucose w/o Glutamine: 1X Liquid
FluxMPS™ RPMI 1640 Medium, High Glucose w/o Glutamine: 1X Liquid
Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid RPMI 1640 medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.
- Quadruple-stage filtration train: 0.1 µm (Prefiltration I) → 0.04 µm (Final filtration I) → 0.1 µm (Prefiltration II) → 0.04 µm (Final filtration II — Polish)
- Endotoxin release specification: < 0.05 EU/mL (USP <85> BET), controlled per manufacturing batch
- RPMI 1640 high-glucose base (4500 mg/L / 4.5 g/L D-glucose) formulated without L-glutamine — supplement at time of use per your protocol
- Sodium bicarbonate-buffered (2000 mg/L) system targeting pH 7.4 under a 5% CO₂ atmosphere
- Prepared with Type 1 water (18.2 MΩ·cm) and filled under ISO Class 5 (Class 100) aseptic conditions
- Manufactured under an ISO 13485:2016 quality management system; final QC and customization at Diagnocine, Totowa NJ
- Custom formulations available — pH, glucose, salts, HEPES, and nutrient composition on request
- Glucose4500 mg/L (4.5 g/L)
- L-GlutamineNot present — supplement as needed
- Sodium Pyruvate110 mg/L
- HEPESNot present
- pH (USP <791>)7.4
- Osmolality (USP <785>)See CoA
- Endotoxin (USP <85>)< 0.05 EU/mL
- Filtration0.1 µm ×2 + 0.04 µm ×2 (Quadruple-stage)
- Storage2–8°C, protect from light
- Shelf Life12 months from date of manufacture, unopened
Engineered where standard media fails
Conventional 0.22 µm-filtered media carry mycoplasma-sized particulates (0.2–0.3 µm), subvisible debris, and inconsistent endotoxin control that accumulate inside microchannels — corrupting biosensor readings and shortening device lifetimes. FluxMPS™ is built to address these failure modes at the filtration stage.
Microchannel-safe purity
0.04 µm final filter retains particulate down to sub-mycoplasma size; USP <788> Method 1 (light obscuration) particulate compliance verified per lot.
Total metabolic control
High-glucose (4.5 g/L) formulation with defined nutrient concentrations, suited for metabolic flux studies and Warburg-effect research; alternative carbon sources available on request.
Ultrapure-grade water
Prepared with Type 1 water (18.2 MΩ·cm), supporting low trace-metal and organic-carbon background for sensitive assays.
Low background for imaging
Ultra-low particulate baseline from quadruple-stage filtration — well suited for confocal microscopy, live-cell biosensors, and TEER measurements.
Rich, stable nutrient profile
Micro-batch precision manufacturing locks in amino acid and vitamin concentrations, supporting lot-to-lot reproducibility for long-term perfusion studies.
Customization on demand
pH, glucose, salts, HEPES, and full nutrient composition available on request. Contact support@diagnocine.com.
Quadruple-stage filtration system
FluxMPS™ RPMI 1640 Medium, High Glucose w/o Glutamine: 1X Liquid is processed through a validated four-stage prefilter/final-filter train reaching a 0.04 µm final pore size — addressing mycoplasma-sized and subvisible particulate that 0.22 µm filtration does not remove.
-
1
0.1 µm Prefiltration I
Removes large particulates, cell debris, and protein aggregates; protects the first 0.04 µm final-filter cartridge.
-
2
0.04 µm Final filtration I
First 0.04 µm pass; retains mycoplasma-sized (0.2–0.3 µm) and other sub-micron particulate not removed by standard 0.22 µm filtration.
-
3
0.1 µm Prefiltration II
Second dedicated prefilter, protecting the second 0.04 µm final-filter cartridge from breakthrough.
-
4
0.04 µm Final filtration II — Polish
Ultimate polishing filter; aseptic fill & finish in a validated ISO Class 5 (Class 100) laminar-flow workstation.
Performance vs. conventional media
Four sequential stages reaching a 0.04 µm final pore size deliver approximately 5× cleaner media by particulate count compared with single-pass 0.22 µm filtration, with USP <788> Method 1 compliance verified on every lot.
© Diagnocine® — DCP-RPMIG-Q1X
Designed for next-generation cell culture platforms
FluxMPS™ RPMI 1640 Medium, High Glucose w/o Glutamine: 1X Liquid is intended for organ-on-a-chip, metabolic research, live-cell imaging, and primary cell models where particulate contamination and endotoxin variation are unacceptable.
Automated Bioreactors & Robotics
An optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant is available for automated bioreactor and robotic perfusion systems requiring the finest particulate exclusion beyond the 0.04 µm Microfluidics Suitable tier described above.
- Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
- Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
- Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs
Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm MPS Grade variant.
Micro Physiological System (MPS) & Chip
Ultra-filtered formulation supports laminar flow integrity and reduces the risk of microchannel clogging.
Warburg Effect & Metabolic Research
High-glucose base with controlled endotoxin background supports metabolic flux analysis in cancer cell models.
iPSC-Derived Models
Ultrapure formulation supports sensitive iPSC differentiation protocols.
Endothelial & Primary Cells
Microchannel-safe purity supports endothelial barrier integrity and TEER-based assays.
Metabolic Flux Analysis
Defined base composition supports isotope tracing and mass-spectrometry-based flux workflows. Not compatible with Agilent Seahorse XF assays, which require bicarbonate-free, phenol red-free medium.
Microscopy & Optical Sensing
Ultra-low particulate load from quadruple-stage filtration supports high-content confocal imaging and biosensor applications.
Lot-release quality parameters
Every production lot of FluxMPS™ RPMI 1640 Medium, High Glucose w/o Glutamine: 1X Liquid undergoes the quality-release battery below before shipment.
| Parameter | Specification |
|---|---|
| Formulation | RPMI 1640 Medium, High Glucose w/o Glutamine: 1X Liquid |
| Appearance | Red-colored, clear solution (phenol red indicator present) |
| pH USP <791> | 7.4 |
| Osmolality USP <785> | See CoA |
| Glucose | 4500 mg/L (4.5 g/L) |
| L-Glutamine | Not present — supplement as needed |
| Sodium Pyruvate | 110 mg/L |
| Phenol Red | Present (5.3 mg/L) |
| Parameter | Specification |
|---|---|
| Endotoxin USP <85> BET | < 0.05 EU/mL (batch release spec.) |
| Sterility USP <71> | No growth after 14 days |
| Mycoplasma | 0.1 µm mycoplasma-retentive filtration (not tested per lot) |
| Particulate ≥10 µm USP <788> Method 1 | Compliant |
| Particulate ≥25 µm USP <788> Method 1 | Compliant |
| Water Purity | Ultrapure Type 1, 18.2 MΩ·cm |
| Manufacturing std. ISO 13485 | ISO 13485:2016 |
| Fill environment | ISO Class 5 (Class 100) |
| Parameter | Specification |
|---|---|
| Storage temperature | 2–8°C, protected from light |
| Freeze-thaw | Not recommended |
| Shelf life | 12 months from date of manufacture, unopened |
| Shipping condition | Cold pack |
| CO₂ requirement | 5% CO₂ (sodium bicarbonate-buffered, 2000 mg/L NaHCO₃) |
| Parameter | Specification |
|---|---|
| Raw material grade | Cell culture / reagent grade |
| Traceability | Full lot documentation, CoA available |
| Manufacturing QMS | ISO 13485:2016 certified |
| UNSPSC | 41116155 — Molecular biology and cell culture growth media (UNv260801) |
| Regulatory alignment | 21 CFR Part 820 (QMSR) aligned |
| Production method | Micro-batch precision manufacturing |
| Intended use | For Research Use Only (RUO) |
Full composition (mg/L)
Complete formulation with CAS numbers, reproduced from manufacturer specification. Custom compositions available on request.
| Component | CAS Number | mg/L |
|---|---|---|
| INORGANIC SALTS | ||
| Calcium nitrate tetrahydrate | 13477-34-4 | 100.000 |
| Magnesium sulfate anhydrous | 7487-88-9 | 48.840 |
| Potassium chloride | 7447-40-7 | 400.000 |
| Sodium bicarbonate | 144-55-8 | 2000.000 |
| Sodium chloride | 7647-14-5 | 6000.000 |
| Sodium phosphate dibasic anhydrous | 7558-79-4 | 800.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| AMINO ACIDS | ||
| Glycine | 56-40-6 | 10.000 |
| L-Arginine hydrochloride | 1119-34-2 | 241.000 |
| L-Asparagine | 70-47-3 | 50.000 |
| L-Aspartic acid | 56-84-8 | 20.000 |
| L-Cystine dihydrochloride | 30189-89-0 | 65.200 |
| L-Glutamic acid | 56-86-0 | 20.000 |
| L-Histidine hydrochloride monohydrate | 5934-29-2 | 20.960 |
| L-Hydroxyproline | 51-35-4 | 20.000 |
| L-Isoleucine | 73-32-5 | 50.000 |
| L-Leucine | 61-90-5 | 50.000 |
| L-Lysine hydrochloride | 657-27-2 | 40.000 |
| L-Methionine | 63-68-3 | 15.000 |
| L-Phenylalanine | 63-91-2 | 15.000 |
| L-Proline | 147-85-3 | 20.000 |
| L-Serine | 56-45-1 | 30.000 |
| L-Threonine | 72-19-5 | 20.000 |
| L-Tryptophan | 73-22-3 | 5.000 |
| L-Tyrosine Disodium Salt | 69847-45-6 | 28.830 |
| L-Valine | 72-18-4 | 20.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| VITAMINS | ||
| Choline chloride | 67-48-1 | 3.000 |
| D-Biotin | 58-85-5 | 0.200 |
| D-Ca-Pantothenate | 137-08-6 | 0.250 |
| Folic acid | 59-30-3 | 1.000 |
| Niacinamide | 98-92-0 | 1.000 |
| Pyridoxine hydrochloride | 58-56-0 | 1.000 |
| Riboflavin | 83-88-5 | 0.200 |
| Thiamine hydrochloride | 67-03-8 | 1.000 |
| Vitamin B12 | 68-19-9 | 0.005 |
| p-Amino benzoic acid (PABA) | 150-13-0 | 1.000 |
| OTHERS | ||
| D-Glucose | 50-99-7 | 4500.000 |
| Glutathione reduced | 70-18-8 | 1.000 |
| Phenol red sodium salt | 34487-61-1 | 5.300 |
| Sodium Pyruvate | 113-24-6 | 110.000 |
| i-Inositol | 87-89-8 | 35.000 |
ISO 13485:2016 manufacturing & compliance
Manufactured under an ISO 13485:2016 QMS, with final packaging, testing, and customization at Diagnocine in Totowa, New Jersey, USA.
ISO 13485:2016 QMS
Full quality management system certification covering manufacturing, testing, and release for every production lot.
Ultrapure Type 1 Water
All media prepared with 18.2 MΩ·cm resistivity water.
ISO Class 5 Fill & Finish
Aseptic filling in validated ISO Class 5 laminar-flow workstations; 21 CFR Part 820 (QMSR) aligned.
Micro-Batch Precision
Small-batch manufacturing supports lot-to-lot nutrient consistency for reproducible perfusion studies.
Endotoxin — USP <85> BET
LAL assay; release specification < 0.05 EU/mL; assay sensitivity 0.005 EU/mL.
Particulate — USP <788> Method 1
Light obscuration particle count confirms ≥10 µm and ≥25 µm compliance on every lot.
Osmolality — USP <785>
Freezing-point osmometry per USP <785>. Result: See CoA.
Documentation — CoA & Full Lot Records
Certificate of Analysis with full QC panel, raw material traceability, and release signatures for every lot.
- Endotoxin — LAL assay, USP <85> Bacterial Endotoxins Test; assay sensitivity 0.005 EU/mL; release specification < 0.05 EU/mL
- pH, osmolality, conductivity, appearance and clarity
- Sterility
How DCP-RPMIG-Q1X (FluxMPS™) compares
Side-by-side comparison against conventional 0.22 µm-filtered alternatives of the same base formulation.
| Parameter | DCP-RPMIG-Q1X (FluxMPS™) | Conventional RPMI 1640 (0.22 µm) | Standard RPMI 1640 alternative |
|---|---|---|---|
| Grade | Microfluidics Suitable | Not specified | Not specified |
| Base Formulation | RPMI 1640, High Glucose w/o Glutamine | RPMI 1640 Standard | RPMI 1640 Equivalent |
| Final filtration pore size | 0.04 µm | 0.22 µm | 0.22 µm |
| Number of filtration stages | 4 stages | 1 stage | 1–2 stages |
| Mycoplasma-retentive filtration | check_circle | cancel | cancel |
| Endotoxin (release specification) | FluxMPS™ — < 0.05 EU/mL | Corning classical liquid media — < 0.25 EU/mL Sigma-Aldrich DMEM complete medium — ≤ 2 EU/mL Gibco classical DMEM — Not specified (recorded per lot) |
|
| USP particulate compliance | check_circle USP <788> Method 1 | cancel | cancel |
| Water quality | Ultrapure Type 1 (18.2 MΩ) | Purified water | Purified water |
| Manufacturing QMS | ISO 13485:2016 | Variable | Variable |
| Microfluidic channel compatibility | check_circle Validated | cancel Risk of clogging | cancel Risk of clogging |
| Custom formulation | check_circle On request | cancel | Limited |
Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".
Frequently asked questions
Common questions about FluxMPS™ RPMI 1640 Medium, High Glucose w/o Glutamine: 1X Liquid and Microfluidics Suitable cell culture media.
Supporting literature
Peer-reviewed publications supporting the scientific rationale for ultra-filtered media and microfluidic cell culture applications.
- Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
- Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
- Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
- Warburg O (1956). On the origin of cancer cells. Science, 123(3191), 309–314. doi:10.1126/science.123.3191.309
- Kim S et al. (2012). Gut-on-a-chip microdevice replicates key functional features of the human intestine. Lab on a Chip, 12(12), 2165–2174. doi:10.1039/c2lc40074j
- Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
- Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
- Schuster B et al. (2020). Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nature Communications, 11, 5271. doi:10.1038/s41467-020-19058-4
- Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175
- Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539
